ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 522
March 31, 1988

CALCIUM ANTAGONISTS[a]
Pharmacology and Clinical Research

Editors and Conference Organizers
P. M. VANHOUTTE, R. PAOLETTI, and S. GOVONI

International Advisory Committee
S. EBASHI, C. FIESCHI, A. FLECKENSTEIN, T. GODFRAIND, L. H. OPIE, H. REUTER, A. SCHWARTZ, W. N. SCOTT, and M. SPEDDING

CONTENTS

Preface. *By* P. M. VANHOUTTE, R. PAOLETTI, and S. GOVONI xiii

Part I. Electrophysiology

Historical Overview: The Calcium Channel of the Heart. *By* ALBRECHT FLECKENSTEIN 1

Calcium Channels in the Heart: Properties and Modulation by Dihydropyridine Enantiomers. *By* H. REUTER, H. PORZIG, S. KOKUBUN, and B. PROD'HOM . 16

Calcium Channel Modulation by Dihydropyridines in Vascular Smooth Muscle. *By* KENT HERMSMEYER, MICHAEL STUREK, and NANCY J. RUSCH 25

Voltage-Dependent Calcium Channel in Intestinal and Vascular Smooth Muscle Cells. *By* T. B. BOLTON, P. I. AARONSON, and I. MACKENZIE..... 32

Poster Papers

Monoclonal Antibody Characterization of the 1,4-Dihydropyridine Receptor of Rabbit Skeletal Muscle. *By* ALBERT T. LEUNG, TOSHIAKI IMAGAWA, and KEVIN P. CAMPBELL 43

Membrane Potential Regulates Dihydropyridine Inhibition of Single Calcium Channels and Contraction of Rabbit Mesenteric Artery. *By* M. T. NELSON, I. LAHER, and J. WORLEY 47

Part II. Biochemistry

Historical Overview: Calcium Ion and Contractile Proteins. *By* SETSURO EBASHI 51

[a]This volume is the result of a conference entitled Calcium Antagonists: Pharmacology and Clinical Research held from February 10 to February 13, 1987 in New York, N.Y., sponsored by Fondazione Giovanni Lorenzini, Giovanni Lorenzini Medical Foundation, and The New York Academy of Sciences.

Vascular Smooth Muscle Sarcoplasmic Reticulum: Function and Mechanisms of Ca^{2+} Release. *By* C. VAN BREEMEN, K. SAIDA, H. YAMAMOTO, K. HWANG, and C. TWORT 60

Calmodulin and Its Activation by Cadmium Ion. *By* WAI YIU CHEUNG 74

Interaction of Calcium with Receptor-Stimulated Phosphoinositide Hydrolysis in Brain and Liver. *By* F. T. CREWS, R. A. GONZALES, R. RAULLI, R. MCELHANEY, N. PONTZER, and M. RAIZADA 88

Presence in Brain of an Endogenous Ligand for Nitrendipine-Binding Sites that Modulates Ca^{2+} Channel Activity. *By* INGEBORG HANBAUER and ENRICO SANNA 96

Cyclic Nucleotides and Calcium Regulation in Heart and Smooth Muscle Cells. *By* JEAN-CLAUDE STOCLET, CHANTAL BOULANGER-SAUNIER, BERNARD LASSEGUE, and CLAIRE LUGNIER 106

Part III. Biochemical Pharmacology

Calcium Antagonist Receptors: Clinical and Physiological Relevance. *By* JOHN A. WAGNER, SANDY E. GUGGINO, IAN J. REYNOLDS, ADELE M. SNOWMAN, AMITAVA BISWAS, BALDOMERO M. OLIVERA, and SOLOMON H. SNYDER 116

Molecular Properties of Structure and Regulation of the Calcium Channel. *By* MICHEL LAZDUNSKI, JACQUES BARHANIN, MARC BORSOTTO, CHRISTIAN COGNARD, CHRISTIE COOPER, THIERRY COPPOLA, MICHEL FOSSET, JEAN-PIERRE GALIZZI, MARLENE M. HOSEY, CHRISTIANE MOURRE, JEAN-FRANÇOIS RENAUD, GEORGE ROMEY, ANNIE SCHMID, and SYLVIE VANDAELE 134

Purification and Reconstitution of Calcium Channel Drug-Receptor Sites. *By* HARTMUT GLOSSMANN, JÖRG STRIESSNIG, LIN HYMEL, and HANSGEORG SCHINDLER 150

Molecular Properties of Dihydropyridine-Sensitive Calcium Channels. *By* MICHAEL J. SEAGAR, MASAMI TAKAHASHI, and WILLIAM A. CATTERALL .. 162

Mechanism of Action of Calcium Channel Modulator Drugs: Identification of a Unique, Labile, Drug-Binding Polypeptide in a Purified Calcium Channel Preparation. *By* PAL L. VAGHY, KIYOSHI ITAGAKI, KUNIHISA MIWA, EDWARD MCKENNA, and ARNOLD SCHWARTZ 176

Plasticity of Neuronal L-Type Calcium Channels. *By* S. GOVONI, F. BATTAINI, S. M. MAGNONI, L. LUCCHI, R. A. RIUS, and M. TRABUCCHI 187

Poster Papers

Dihydropyridine-Sensitive Ca^{2+} Channels in Brain Are Involved in the Central Nervous System Hyperexcitability Associated with Alcohol Withdrawal States. *By* J. M. LITTLETON and H. J. LITTLE 199

Calcium Channel Binding Sites in Human Brain. *By* RÉMI QUIRION, SAMARTHJI LAL, ANDRÉ OLIVIER, YVES ROBITAILLE, N. P. VASSAVAN NAIR, ROBERT M. FORD, and JOSEPH G. STRATFORD 203

Morphine Treatment Increases [^{3}H]Nimodipine Binding Sites in Rat Brain: Attenuation by Nimodipine and Other Ca^{2+} Channel Antagonists of Naloxone-Precipitated Withdrawal in Morphine-Dependent Animals. *By* VICKRAM RAMKUMAR and ESAM E. EL-FAKAHANY 207

Part IV. Physiology and Pharmacology

Actions of Calcium on Smooth Muscle: Historical Overview. *By* DAVID F. BOHR 210

Calcium and Vascular Myogenic Tone. *By* ISMAIL LAHER, JOYCE HWA, and JOHN A. BEVAN 216

Calcium and Activation of the Release of Endothelium-Derived Relaxing Factor. *By* GABOR M. RUBANYI and PAUL M. VANHOUTTE 226

Calcium Antagonism and Vascular Smooth Muscle. *By* J. M. VAN NUETEN, W. J. JANSSENS, and P. M. VANHOUTTE 234

Antagonists and Activators at Calcium Channels: Effects in the Gastrointestinal Tract. *By* MICHAEL SPEDDING 248

Effects of Calcium "Antagonists" on Vertebrate Skeletal Muscle Cells. *By* L. A. HELLAND, J. R. LOPEZ, S. R. TAYLOR, G. TRUBE, and L. A. WANEK. 259

The Effect of Calcium Channel Antagonists on Peripheral Neurones. *By* RICHARD J. MILLER, DOUGLAS A. EWALD, AARON P. FOX, LANE D. HIRNING, EDWIN W. MCCLESKEY, TERESA M. PERNEY, MICHAEL STUREK, STANLEY A. THAYER, RICHARD W. TSIEN, and MARY W. WALKER 269

Do Dihydropyridine-Sensitive Calcium Channels Play a Role in Neurosecretion in the Central Nervous System? *By* TIMOTHY J. TURNER and STANLEY M. GOLDIN 278

Calcium Entry and Activation of Endocrine Cells. *By* WILLY J. MALAISSE 284

Poster Papers

Is the Felodipine-Resistant Component of the Alpha-Adrenergic Responses in Portal Vein Due to Inhibition of Ca^{2+} Extrusion through the Na^{+}/Ca^{2+} Exchanger? *By* B. JOHANSSON, B. LJUNG, and A. NILSSON 296

Nisoldipine Enhances Capillary Recruitment in the Heart. *By* PAUL F. MCDONAGH 298

Role of Calcium Channels in the Rat Esophageal Tunica Muscularis Mucosae. *By* S. E. OHIA, Y. D. CHEUNG, D. BIEGER, and C. R. TRIGGLE 301

PN 200-110, a Calcium Antagonist with High Potency and Selectivity for Vascular Smooth Muscle. *By* URS T. RÜEGG, GÜNTER SCHOLTYSIK, NIGEL S. COOK, ARNOLD VOGEL, and ROBERT P. HOF 304

Calcium Antagonist Enantiomers Discriminate between Vascular and Myocardial Calcium Channels in the Retrogradely Perfused Rat Heart. *By* F. TH. M. VAN AMSTERDAM, M. HAAS, and J. ZAAGSMA 306

The Mode of Action of Dihydropyridines in Vascular Smooth Muscle: Correlated Binding and Mechanical Studies. *By* M. WIBO and T. GODFRAIND 309

Part V. Modulatory Influences

Calcium Channels in Smooth Muscle. *By* T. GODFRAIND 312

Calcium Transients in Smooth Muscle. *By* KATHLEEN G. MORGAN, ARLENE BRADLEY, and TIA T. DEFEO 328

The Effects of Ca^{2+} Antagonists on Isolated Rat and Rabbit Mesenteric Resistance Vessels: What Determines the Sensitivity of Agonist-Activated Vessels to Ca^{2+} Antagonists. *By* CYNTHIA CAUVIN, MAITE TEJERINA, OK HWANG, MIEKO KAI-YAMAMOTO, and CORNELIS VAN BREEMEN 338

Receptor Subtypes Involved in the Action of Calcium Entry Blockers. *By* P. A. VAN ZWIETEN and P. B. M. W. M. TIMMERMANS 351

The Relationship of Receptor Reserve and Agonist Efficacy to the Sensitivity of α-Adrenoceptor-Mediated Vasopressor Responses to Inhibition by Calcium Channel Antagonists. ROBERT R. RUFFOLO, JR. and ANDREW J. NICHOLS 361

Poster Paper

Arguments Against the Role of Receptor Reserve as a Determinant of the Sensitivity of α_1-Adrenoceptor-Mediated Pressor Responses to Inhibition by Ca^{2+} Entry Blockers in the Pithed Rat. *By* PIETER B. M. W. M. TIMMERMANS and MARTIN J. M. C. THOOLEN 377

Part VI. Pathophysiology

Ca^{2+} Antagonists and Vascular Disease. *By* PAUL M. VANHOUTTE 380

Calcium Antagonists and Low Density Lipoprotein Receptors. *By* R. PAOLETTI, F. BERNINI, R. FUMAGALLI, M. ALLORIO, and A. CORSINI 390

The Effect of Calcium Antagonists on Intimal Cell Proliferation in Atherogenesis. *By* EBERHARD BETZ 399

Calcium Antagonists as Antiatherogenic Agents. *By* PHILIP D. HENRY 411

Protection of Arterial and Arteriolar Wall Structure by Specific Calcium Antagonists. *By* M. FREY, J. ZORN, A. FLECKENSTEIN, and G. FLECKENSTEIN-GRÜN 420

Pathophysiology of Cardiomyocytes. *By* M. BORGERS, L. VER DONCK, and G. VANDEPLASSCHE 433

Metabolism of Arachidonic Acid. *By* S. MONCADA and E. A. HIGGS 454

A Potential Role of Calcium Ions in Early Ischemic and Reperfusion Arrhythmias. *By* L. H. OPIE, W. A. COETZEE, S. C. DENNIS, and F. T. THANDROYEN 464

Brain Ischemia as a Target for Ca^{2+} Entry Blockers. *By* A. WAUQUIER, D. ASHTON, and G. H. C. CLINCKE 478

Pharmacological Basis and Therapeutic Efficacy of Flunarizine in Peripheral Artery Disease. *By* T. DI PERRI, F. LAGHI PASINI, S. PECCHI, L. DOMINI, L. RALLI, M. MATERAZZI, V. DE FRANCO, A. MONACI, and L. CECCATELLI 491

Ischemic Vasoconstriction and Parenchymal Brain pH. *By* FREDRIC B. MEYER, THORALF M. SUNDT, JR., ROBERT E. ANDERSON, and PHILLIP TALLEY 502

Poster Papers

Amlodipine: Long-Term Natriuretic and Antihypertensive Activity in Spontaneously Hypertensive Rats with Developing and Established Hypertension. *By* R. A. BURGES, D. G. GARDINER, A. J. CARTER, and F. F. MCKAY 516

The Antiatherosclerotic Effect of Anipamil in Cholesterol-Fed Rabbits. *By* A. L. CATAPANO, F. M. MAGGI, and U. CICERANO 519

Long-Lasting Protective Effect of Anipamil, a New Calcium Entry Blocker, against Myocardial Ischemia and Reperfusion Damage. *By* R. FERRARI, C. CECONI, S. CURELLO, A. CARGNONI, R. RADDINO, G. CIAMPALINI, and O. VISIOLI 522

Effect of Nisoldipine on Diet-Induced Atherosclerosis in Rabbits. *By* K. FRONEK 525

Cardioprotective Actions of Nisoldipine in Postreinfusion Myocardial Ischemia. *By* RICHARD K. MENTLEY and ALLAN M. LEFER 527

B 844-39, a New Dihydropyridine Derivative with Slow Onset and Long Duration of Hypotensive Action, in Comparison with Nitrendipine. *By* K. H. SANDERS, N. KOLASSA, and B. CETTIER 531

Effect of Verapamil on Doxorubicin-Induced Cardiomyopathy. *By* F. PICCININI, E. MONTI, L. FAVALLI, and F. VILLANI 533

Part VII. Cardiovascular Diseases

Control of Cardiac Arrhythmias by Calcium Antagonism. *By* KOONLAWEE NADEMANEE and BRAMAH N. SINGH 536

Calcium Antagonists in Heart Failure. *By* SPENCER H. KUBO, MARIA TERESA OLIVARI, and JAY N. COHN 553

Calcium Antagonists for Angina Pectoris. *By* P. G. HUGENHOLTZ 565

Calcium Antagonists and Their Potential for Antihypertensive Therapy. *By* F. R. BÜHLER and W. KIOWSKI 584

Myocardial Protection. *By* W. FLAMENG 600

Clinical Use of Calcium Antagonists in Peripheral Circulatory Disease. *By* J. DORMANDY 611

Poster Papers

Influence of Verapamil on the Body Sodium/Fluid Volume State and Noradrenergic-Dependent Blood Pressure Regulation in Patients with Essential Hypertension. *By* C. BERETTA-PICCOLI, C. MARONE, P. STÄDLER, W. H. ZIEGLER, W. RIESEN, and C. PUSTERLA 621

Acute Effects of Felodipine on Regional Blood Flow in Chronic Heart Failure. *By* G. BINETTI, R. SPADONI, I. RUBINO, E. VARANI, R. M. FERRETTI, S. PANCALDI, V. CERVI, and B. MAGNANI 623

Predictive Factors of the Acute and Chronic Blood Pressure Fall Induced by the Calcium Antagonist Nicardipine. *By* GILLES CHATELLIER, PASCAL CLUZEL, MARC BELLET, JOSEPH RIVALAN, PIERRE CORVOL, and JOËL MENARD 625

Cardiovascular Effects of Dihydropyridine Calcium Channel Antagonists and Their Relation to Drug Levels in Plasma. *By* K.-H. GRAEFE, R. ZIEGLER, W. WINGENDER, K.-D. RÄMSCH, and G. AHR 628

Comparative Evaluation of Two Calcium Antagonists, Nicardipine and Nifedipine, in Patients with Mild to Moderate Chronic Heart Failure: A Noninvasive Study. *By* C. MAZZOLA, E. E. GUFFANTI, A. VACCARELLA, D. TURRI, M. NAZZARI, and G. FIORELLA 630

Chronic Administration of Slow-Release Nifedipine Improves Arterial Compliance in Elderly Hypertensives with Systolic Hypertension. *By* S. Novo, G. Davì, E. Nardi, F. Zingone, M. Floridia, G. Centineo, G. Noto, G. Licata, and A. Strano 632

Effects of Middle-Term Treatment with Nifedipine on Hemodynamic Parameters and on Left Ventricular Function in Hypertensive Patients. *By* R. Scaglione, G. Parrinello, G. Capuana, M. A. Dichiara, G. Mazzola, N. Asta, S. Novo, and G. Licata 636

Part VIII. Neurological Disease

Historical Overview: Calcium, Ischemia, and Death of Brain Cells. *By* Bo K. Siesjö 638

Therapeutic Window for Pharmacological Treatment in Acute Focal Cerebral Ischemia. *By* C. Fieschi, C. Argentino, G. L. Lenzi, L. Fantozzi, M. L. Sacchetti, A. Pace, M. Rasura, S. Bastianello, L. Bozzao, E. Zanette, C. Buttinelli, F. Giubilei, and P. Pantano 662

Use of a Calcium Antagonist in Aneurysmal Subarachnoid Hemorrhage. *By* Lennart Brandt, Bengt Ljunggren, Hans Säveland, and Karl-Erik Andersson 667

Clinical and Experimental Evidence for a Role of Calcium Entry Blockers in the Treatment of Migraine. *By* Egilius L. H. Spierings 676

Calcium Entry Blockers in the Treatment of Vertigo. *By* J. Olesen. 690

Pharmacology of Nimodipine: A Review. *By* A. Scriabine and W. van den Kerckhoff 698

Poster Papers

Improvement of Parkinsonism after Withdrawing Long-Term Flunarizine Treatment. *By* F. Benvenuti, A. Baroni, S. Bandinelli, R. Corradetti, N. Marchionni, F. M. Antonini, and T. Pantaleo 707

Flunarizine in Epilepsy. *By* C. D. Binnie 710

Safety Profile of Flunarizine: A Retrospective Study in Migraine and Cerebrovascular Disorders. *By* G. Bono, N. Martucci, P. Merlo, R. Cerbo, G. Nappi, and A. Agnoli 712

Specific Effects of Nimodipine on the Auditory System. *By* P. J. Jastreboff and J. F. Brennan 716

Pharmacokinetics and Metabolism of Radiolabeled Nimodipine. *By* J. Lettieri, G. Krol, K.-D. Rämsch, S. Yeh, F. G. McMahon, J. Ryan, A. Jain, and B. Kamath 719

Calcium Entry Blockers in the Prophylaxis of Migraine. *By* Jes Olesen 720

Lumbar and Cisternal Cerebrospinal Fluid Level of Arachidonate Metabolites in Nimodipine-Treated Patients after Subarachnoid Hemorrhage. *By* Riccardo Rodriguez y Baena, Paolo Gaetani, Vittorio Silvani, Guido Grignani, Giancarlo Folco, and Pietro Paoletti 723

New Opportunities with a Calcium Overload Blocker in Brain Protection? *By* T. Peters and K. U. Seiler 727

Nimodipine Oral Treatment in Subarachnoid Hemorrhage: Overview of Results from Three Randomized Controlled Trials. *By* G. Taquoi, L. Porto, and D. Tettenborn 729

Part IX. Other Therapeutic Indications

The Role of Calcium Channel Blockers in Reactive Airway Disease. *By* ROBERT G. TOWNLEY, J. CHENG, A. K. BEWTRA, N. NAIR, R. HOPP, and D. K. AGRAWAL 732

Calcium Antagonists and Dysmenorrhea. *By* K.-E. ANDERSSON 747

Protection of Liver by Calcium Entry Blockers. *By* RONALD G. THURMAN, ELIZABETH APEL, MOSTAFA BADR, and JOHN L. LEMASTERS 757

Calcium Antagonists and the Renal Hemodynamic Response to Vasoconstrictors. *By* RODGER LOUTZENHISER and MURRAY EPSTEIN 771

Effects of Calcium Antagonists on Renal Function. *By* JOHN H. BAUER and GARRY P. REAMS 785

Poster Papers

Dihydropyridine Calcium Channel Blocking Agents in Hepatotoxic and Ethanol-Induced Liver Cell Injury. *By* ERWIN J. LANDON, MELANIE SURBER, and B. V. RAMA SASTRY 793

Nitrendipine: An Antidote to the Lethal Toxicity of Cocaine. *By* G. NAHAS, R. TROUVÉ, C. LATOUR, M. SITBON, and J.-F. DEMUS 796

Index of Contributors 799